People: BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

2 Jul 2020
Change (% chg)

$-1.33 (-2.49%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

O'Neill, Vincent 

Dr. Vincent J. O'Neill M.D. serves as Chief Medical Officer of the Company. He served as the Chief Medical Officer of Mirna Therapeutics, Inc. from April 2016 to May 2017. From June 2014 to May 2016, he served as the Chief Medical Officer of Exosome Diagnostics, Inc., a diagnostics company. From 2012 to 2014, Dr. O'Neill was global head Personalized of Medicine and Companion Diagnostics at Sanofi S.A., a pharmaceutical company. From 2009 to 2012, Dr. O'Neill served as Group Director at Genentech, Inc. where he was involved in the expanded approval of products such as Avastin and Tarceva. From 2006 to 2009, Dr. O'Neill served as Director, Discovery Medicine at GlaxoSmithkline plc. Dr. O'Neill holds an M.D., MBChd and M.Sc. in Pathology from the University of Glasgow, UK.

Basic Compensation

Total Annual Compensation, USD 508,967
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,200
Fiscal Year Total, USD 510,167

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --